1st Edition

Handbook of Therapeutic Biomarkers in Cancer

Edited By Sherry X. Yang, Janet E. Dancey Copyright 2013
    518 Pages 20 Color & 18 B/W Illustrations
    by Jenny Stanford Publishing

    In this volume, a team of internationally recognized experts provide an in-depth description of therapeutic biomarkers across a broad area of cancer research and oncology. With a wealth of information to specific therapies, each chapter focuses on a class of targeted chemotherapy agents. The book describes established and evolving diagnostic tests for therapeutic biomarkers that predict benefit, response, resistance, or drug side effects from specific therapeutic interventions. This volume is an essential handbook for health professionals and scientists researching current applicable biomarkers in oncology.

    Overview: Therapeutic Biomarkers in Cancer, Sherry X. Yang and Janet E. Dancey
    Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer, Lisa M. McShane, Edward L. Korn and Boris Freidlin
    Role of Biomarkers in Clinical Development of New Cancer Therapies, Helen X. Chen
    HER2 as a Prognostic and Predictive Biomarker in Cancer, Suparna Wedam and Stan Lipkowitz
    Hormone Receptors and Endocrine Therapy in Breast Cancer, Chia C. Portera and Sherry X. Yang
    Predictive Biomarkers for Epidermal Growth Factor Receptor (EGFR) Agents in Non-Small Cell Lung Cancer, John Hilton, Penelope A. Bradbury, and Janet E. Dancey
    Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer, Jose G. Monzon and Janet E. Dancey
    Targeting BCR-ABL for Molecular Therapy of Chronic Myelogenous Leukemia, Shamudheen Rafiyath, Guoqing Wei, and Delong Liu
    Gastrointestinal Stromal Tumors (GISTs): From Molecular Pathogenesis to Therapy, Joaquina Baranda, Rashna Madan and Andrew K. Godwin
    PML/RARa Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment, Alicja Gruszka and Myriam Alcalay
    Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluouracil Toxicity, Eva Gross and André B. P. van Kuilenburg
    UGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced Toxicity, Kellie Reece and William D. Figg
    The 21-Gene Recurrence Score and Benefit of Chemotherapy in Estrogen Receptor-Positive Breast Cancer, Petra Rietchel and Joseph A. Sparano
    MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients, Sonal J. Desai and Tianhong Li
    BRCA mutation and PARP Inhibitors, Marcie K. Weil, Shivaani Kummar, James H. Doroshow, and Alice P. Chen
    EML4-ALK Fusion Gene and Therapy with ALK-targeted Agents in Non-Small Cell Lung Cancer, Vimal Patel, MD and Biren Saraiya
    BRAF-Targeted Therapy in Metastatic Melanoma, Noori Kim and April C. Deng


    Sherry X. Yang, Janet E. Dancey